davide ciardielloa medical oncologist in the Department of Gastrointestinal and Neuroendocrine Tumors at the European Institute of Oncology, shared the following post linkedin He added of a recent article he and a colleague co-authored:
“In recent years, the prognostic and predictive role of HER-2 in colon cancer has become a subject of debate.
Recent evidence supports that changes in HER-2 are associated with poor prognosis. At the same time, the predictive role of ERBB2 amplification does not indicate a clear mechanism of resistance to anti-EGFR drugs (HER-2 IHC 2+ cases?). The effects of ERBB2 mutations are even less known.
In this scenario, we evaluated the potential role of HER-2 alterations in response to FOLFIRI + cetuximab in the framework of the CAPRI-2 GOIM clinical trial, taking into account the limitations of the exploratory analysis performed on a small number of cases.
At baseline, HER-2 assessment was performed with liquid biopsy (and in most cases tissue) CGP testing using the FoundationOne platform.
In total, 6% of cases had ERBB2 amplification and/or mutations.
Our analysis confirmed the poor prognostic role of HER-2.
At the same time, we observed a very short PFS in almost all cases of patients with ERBB2 mutations. These data are consistent with those of Germani MM et al. JCO 2025.
Although larger case studies are needed to confirm the results, I am increasingly convinced that pathogenic mutations in ERBB2 represent a mechanism of resistance to anti-EGFR drugs in mCRC. ”
title: HER-2 genetic alterations as a biomarker in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: results of the CAPRI-2 GOIM study
author: D. Ciardiello, L. Boscolo Biello, S. Napolitano, E. Martinelli, T. Troiani, E. Cioli, TP Latiano, E. Maiello, P. Parente, A. Avallone, A. De Stefano, R. Bordonaro, AE Russo, C. Rotesoliere, S. Vararelli, S. Pisconti, C. Nisi, E. Tamburini, MG Viola, S. Ronaldi, C. Cremolini, D. Iacono, P. Tagliaferri, F. Pietrantonio, G. Tortola, G. Rosati, MG Zampino, G. Crigliano, A. Febraro, N. Normanno, F. De Vita, N. Fazio, F. Ciardiello, G. Martini
please read Full article above ESMO Gastrointestinal Oncology
See more featured articles Davide Ciardiello.